New York Menlo Park Washington DC London Paris | Madrid Tokyo Beijing Hong Kong |

Jeffrey R. O'Brien | ||
Davis Polk & Wardwell LLP 99 Gresham Street London EC2V 7NG | 020 7418 1376 tel 020 7710 4893 fax jeffrey.obrien@davispolk.com |
Form 20-F for the Fiscal Year Ended December 31, 2009 Filed February 11, 2010 File Number: 333-82318 |
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
In order to ensure the completeness and accuracy of the Company’s response, it will be conducting a detailed review of the items concerned in respect of the above filing.
The Company anticipates being able to complete this review and provide a response to the SEC by Wednesday, June 30.
Very truly yours,
/s/ Jeffrey O’Brien
Jeffrey O’Brien
cc: Jesper Brandgaard
Novo Nordisk A/S
Via Edgar Submission
A New York limited liability partnership. The principal place of business of the partnership in Great Britain
is the address set forth above at which a list of the partners' names is open for inspection.